Welcome to our dedicated page for TAKEDA PHARMACEUTICAL CO SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TAKEDA PHARMACEUTICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TAKEDA PHARMACEUTICAL CO's regulatory disclosures and financial reporting.
Takeda Pharmaceutical Company Limited has a holder planning a resale of its American Depositary Shares under Rule 144. The plan covers 51,579 ADSs to be sold through Interactive Brokers LLC on the NYSE, with an aggregate market value of $863,947.36. The securities relate to Restricted Stock Unit Awards – Vested, with 109,202 ADSs acquired as compensation on July 1, 2026, of which a portion is covered by this planned sale as of a proposed sale date of July 13, 2026.
Takeda Pharmaceutical Company Limited filed to permit the sale of 33,696 American Depositary Shares (ADSs) through Interactive Brokers LLC on 07/13/2026 on the NYSE. The proposed sale has an aggregate market value of $564,406.02.
Over the prior three months, 126,794 ADSs were sold on 07/01/2026, arising from Restricted Stock Unit Awards – Vested granted as compensation.
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs) through Interactive Brokers LLC on the NYSE. The proposed sale covers 33,454 ADSs with an approximate aggregate value of $560,351.40 as of a planned sale date of July 13, 2026. In the prior three months, 65,890 ADSs were involved in transactions tied to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation-related activity.
An affiliate of Takeda Pharmaceutical Company Limited plans to sell up to 27,197 American Depositary Shares (ADSs) of Takeda through Interactive Brokers LLC on or after July 13, 2026 under Rule 144. These ADSs come from 61,830 ADSs acquired on July 1, 2026 via vested Restricted Stock Unit Awards granted as compensation. The ADSs are listed on the NYSE, with 143,310,556 ADSs outstanding.
Takeda Pharmaceutical Company Limited is registering the potential sale of 19,754 American Depositary Shares (ADSs), corresponding to vested Restricted Stock Unit Awards. The ADSs were acquired as compensation on July 1, 2026 and are proposed to be sold through Interactive Brokers LLC on the NYSE. The filing indicates an aggregate market value of approximately $123,072.06 for the ADSs covered.
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs). The planned sale covers up to 4,319 ADSs of Takeda, to be executed through Interactive Brokers LLC on or after July 13, 2026 on the NYSE. The securities to be sold were received as Restricted Stock Unit awards that vested on July 1, 2026, with a separate entry showing 13,988 ADSs acquired on that date as compensation.
Takeda Pharmaceutical Company Limited submitted a notice for the proposed sale of American Depositary Shares (ADSs) under Rule 144. The notice covers up to 7,889 ADSs, to be sold through Interactive Brokers LLC on the NYSE on or after July 13, 2026, with an indicated aggregate market value of $132,148.97. It also lists activity in the prior three months, including 25,586 ADSs related to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation.
Takeda Pharmaceutical Company Limited reports a planned sale of 15,188 American Depositary Shares (ADSs) of its stock through Interactive Brokers LLC on the NYSE on July 13, 2026, with an aggregate market value of $254,398.88. The ADSs relate to previously issued equity compensation, and 143,310,556 shares of the issuer’s securities are reported as outstanding. During the prior three months, 38,982 ADSs tied to vested Restricted Stock Unit awards were sold on July 1, 2026 for compensation purposes.
Takeda Pharmaceutical Company Limited has filed a notice for the potential sale of American Depositary Shares (ADSs) under Rule 144. The planned transaction involves 50,582 ADSs, which were acquired on July 1, 2026 through vested Restricted Stock Unit Awards. The ADSs are listed on the NYSE and the broker named for the transaction is Interactive Brokers LLC. The filing characterizes the acquisition as compensation-related and indicates that the securities to be sold are ADSs of Takeda.
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares (ADSs) has filed to sell up to 179,239 ADSs through Interactive Brokers LLC on the NYSE, with a stated aggregate market value of $3,002,257.72. The transaction is referenced with a date of July 13, 2026.
The ADSs relate to Restricted Stock Unit awards that vested on July 1, 2026, categorized as compensation, with 358,730 ADSs shown in connection with those vested awards. No securities sold during the past three months are listed.